SEC Form 4/A · accession 0001209191-18-006131
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owners
CELGENE CORP
10% Owner
Celgene European Investment Co LLC
10% Owner
Celgene Alpine Investment Co., LLC
10% Owner
Celgene Switzerland LLC
10% Owner
Period of report
Jan 23, 2018
Accepted (ET)
Jan 31, 2018 · 8:39 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 23, 2018 | P | 851,154 | $67.00 | A | 1,374,599 | D | |
| Common StockF2 | holding | — | — | — | 5,343,834 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018.
- F2Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC, 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC, and 4,010,926 shares are owned directly by Celgene European Investment Company LLC, each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.